Literature DB >> 31377471

Comparative study of the efficacy and pharmacokinetics of reduning injection and atomization inhalation.

Guangping Zhang1, Yingfei Li2, Tengfei Chen2, Yunhang Gao2, Jing Sun2, Wei Yang2, Ling Song2, Ping Su2, Meng Ma2, Zhongxiu Zhang2, Haijing Zhang2, Yifei Yang2, Han Li2, Zuguang Ye3, Hongping Hou4.   

Abstract

The effects of Reduning injection and nebulized inhalation for treating upper respiratory tract infections were compared, including anti-bacterial, anti-viral, anti-inflammatory, anti-pyretic, anti-tussive, and anti-phlegm. Using chlorogenic acid, cryptochlorogenic acid, neochlorogenic acid, and geniposide as the index components, the pharmacokinetics and tissue distributions were compared. Influenza virus PR8-infected mice in the Reduning groups showed significantly reduced mortality and prolonged survival time. The white blood cell count was significantly reduced in the 20- and 10-min groups. Inhalation significantly decreased the temperature from 2 h in the 20- and 10-min groups. Inhalation significantly reduced the cough rate but not cough latency. Phenol red excretion was significantly increased in all Reduning groups. The elimination half-life of geniposide after inhalation in male and female rats was 2.05-5.28 and 4.03-10.4 h, respectively, which was much greater than after injection. Regarding tissue distribution, the injection dose (2 mL/kg) was 50 times the inhalation dose, and maximum serum concentration (Cmax) and AUCINF_obs of the four components in the trachea and lung were 0.95-11.1 and 0.59-4.36 times the inhalation values, respectively. Plasma Cmax and AUCINF_obs were 160-637 and 22.7-180 times the inhalation values, respectively. Atomized Reduning dose was equivalent to 1/90 of the mouse injection dose, and the effects of inhalation were similar or superior to those of injections. Atomization inhalation is targeted to the lungs, so systemic drug exposure was greatly reduced and lung concentration was high, which may increase the efficacy and reduce the safety risks associated with injections.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Pharmacodynamics; Pharmacokinetics; Reduning inhalation solution; Reduning injection

Mesh:

Substances:

Year:  2019        PMID: 31377471     DOI: 10.1016/j.biopha.2019.109226

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Pharmacokinetic Study of Coadministration with Cefuroxime Sodium for Injection Influencing ReDuNing Injection-Derived Seven Phytochemicals and Nine Metabolites in Rats.

Authors:  Qiulong Zhao; Chunxue Wang; Jiaxin Cheng; Hui Yan; Ling Wang; Dawei Qian; Jinao Duan
Journal:  J Anal Methods Chem       Date:  2022-07-02       Impact factor: 2.594

2.  Reduning Injection versus Neuraminidase Inhibitors in the Treatment of Influenza: A Systematic Review and Meta-Analysis.

Authors:  Guo-Zhen Zhao; Bo Li; Ya-Fan Wang; Shi-Qi Guo; Yuan Du; Qiu-Xiao Ma; Yu-Hong Guo; Qing-Quan Liu
Journal:  Chin J Integr Med       Date:  2022-05-04       Impact factor: 2.626

Review 3.  Chinese herbal injections for coronavirus disease 2019 (COVID-19): A narrative review.

Authors:  Xiao-Bin Zhu; Meng Guo; Zhi-Hui Zhang; Li-Hua Sun; Lei Liu; Li-Juan Zhou; Chun-Lei Shan; Yi Yang; Lian-Di Kan; Liu-Cheng Li
Journal:  Integr Med Res       Date:  2021-09-30

4.  Clinical Observation of Reduning Combined with Recombinant Human Interferon α-2b in the Treatment of Children with Viral Pneumonia.

Authors:  Zhuangzhuang Li; Lingling Xie; He Wang; Shugen Wang; Jinguang Wu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-14       Impact factor: 2.650

5.  Pharmacokinetics of baicalin and oroxyloside in plasma and different tissues of rats after transnasal aerosol inhalation and intravenous injection of Tanreqing.

Authors:  Teng-Fei Chen; Ling Song; Yun-Hang Gao; Han Li; Jian-Liang Li; Hong-Ping Hou; Bo Peng; Hui-Ying Wang; Wen-Hao Cheng; Zu-Guang Ye; Ying-Fei Li; Guang-Ping Zhang
Journal:  Front Pharmacol       Date:  2022-08-22       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.